Arcus Biosciences (RCUS) News Today $16.47 +0.74 (+4.70%) (As of 11/7/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Arcus Biosciences Reports Q3 2024 ResultsNovember 7 at 11:18 PM | markets.businessinsider.comHold Rating for Arcus Biosciences Amid Uncertainty and Competitive ChallengesNovember 7 at 6:16 PM | markets.businessinsider.comBarclays Sticks to Its Buy Rating for Arcus Biosciences (RCUS)November 7 at 6:16 PM | markets.businessinsider.comArcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...November 7 at 6:16 PM | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPSArcus Biosciences (NYSE:RCUS - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.07. The business had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative net margin of 100.81% and a negative return on equity of 42.86%. The company's quarterly revenue was up 50.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.94) EPS.November 7 at 2:25 PM | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of "Buy" from AnalystsArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned a consensus rating of "Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given aNovember 7 at 1:54 AM | marketbeat.comArcus Biosciences, Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 6 at 11:43 PM | seekingalpha.comArcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline UpdateNovember 6 at 4:22 PM | businesswire.comExpert Outlook: Arcus Biosciences Through The Eyes Of 8 AnalystsNovember 6 at 10:10 AM | benzinga.comArcus Biosciences (NYSE:RCUS) Given Neutral Rating at HC WainwrightHC Wainwright reiterated a "neutral" rating and issued a $20.00 target price on shares of Arcus Biosciences in a report on Wednesday.November 6 at 8:36 AM | marketbeat.comWhat To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 EarningsNovember 6 at 5:08 AM | uk.finance.yahoo.comArcus Biosciences announces results from Part 1 of ARC-10 trialNovember 6 at 5:08 AM | markets.businessinsider.comArcus Biosciences Says Domvanalimab Plus Zimberelimab Improved Overall Survival In ARC-10November 6 at 5:08 AM | markets.businessinsider.comArcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual MeetingOctober 30, 2024 | finance.yahoo.comArcus Biosciences (RCUS) Set to Announce Earnings on WednesdayArcus Biosciences (NYSE:RCUS) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638380)October 30, 2024 | marketbeat.comArcus Biosciences: Advancing On Several FrontsOctober 29, 2024 | seekingalpha.comBarclays Increases Arcus Biosciences (NYSE:RCUS) Price Target to $29.00October 29, 2024 | americanbankingnews.comArcus Biosciences’ Casdatifan Shows Promising Efficacy and Safety in Phase 1 Trial, Supporting Buy RatingOctober 25, 2024 | markets.businessinsider.comArcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Should You Sell?Arcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Here's WhyOctober 25, 2024 | marketbeat.comPrecision BioSciences to Report Q3 Earnings: What's in the Cards?October 25, 2024 | uk.finance.yahoo.comArcus Biosciences price target raised to $29 from $25 at BarclaysOctober 25, 2024 | markets.businessinsider.comArcus Biosciences: Neutral Rating Amid Early-Stage Data Uncertainties and Competitive Market ChallengesOctober 25, 2024 | markets.businessinsider.comArcus Biosciences Announces New Employment Inducement GrantsOctober 24, 2024 | businesswire.comArcus Biosciences (NYSE:RCUS) Sees Large Volume Increase - Should You Buy?Arcus Biosciences (NYSE:RCUS) Sees Strong Trading Volume - What's Next?October 24, 2024 | marketbeat.comArcus Biosciences Shares Rise After Kidney Cancer Drug Shows Promise in Early-Stage TrialOctober 24, 2024 | marketwatch.comFirst Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney CancerOctober 24, 2024 | businesswire.comArcus Biosciences initiated with a Neutral at H.C. WainwrightOctober 23, 2024 | markets.businessinsider.comWhat is HC Wainwright's Forecast for RCUS Q3 Earnings?Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities research analysts at HC Wainwright issued their Q3 2024 earnings estimates for shares of Arcus Biosciences in a research report issued on Monday, October 21st. HC Wainwright analyst E. Bodnar forecasts that the company will earn ($1.05)October 23, 2024 | marketbeat.comArcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline UpdateOctober 22, 2024 | businesswire.comHC Wainwright & Co. Initiates Coverage of Arcus Biosciences (RCUS) with Neutral RecommendationOctober 22, 2024 | msn.comArcus Biosciences (RCUS) Gets a Buy from Truist FinancialOctober 22, 2024 | markets.businessinsider.comHold Rating on Arcus Biosciences Amid Mixed Drug Pipeline Results and UncertaintiesOctober 22, 2024 | markets.businessinsider.comArcus Biosciences (NYSE:RCUS) Shares Gap Down - Time to Sell?Arcus Biosciences (NYSE:RCUS) Shares Gap Down - What's Next?October 21, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Receives New Coverage from Analysts at HC WainwrightHC Wainwright started coverage on shares of Arcus Biosciences in a research report on Monday. They set a "neutral" rating and a $20.00 price objective for the company.October 21, 2024 | marketbeat.comBarclays Issues a Buy Rating on Arcus Biosciences (RCUS)October 17, 2024 | markets.businessinsider.comSG Americas Securities LLC Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS)SG Americas Securities LLC trimmed its stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 76.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,069 shares of the company's stock after sellingOctober 17, 2024 | marketbeat.comBalanced Outlook: Hold Rating on Arcus Biosciences Amid Pipeline Challenges and Market UncertaintyOctober 16, 2024 | markets.businessinsider.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of "Buy" from AnalystsArcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendationOctober 13, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comArcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...October 10, 2024 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) Stock Price Down 5.1% - Here's What HappenedArcus Biosciences (NYSE:RCUS) Shares Down 5.1% - Here's WhyOctober 10, 2024 | marketbeat.comArcus Biosciences Announces New Employment Inducement GrantsOctober 9, 2024 | businesswire.comArcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR SymposiumOctober 9, 2024 | finance.yahoo.comArcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share PriceOctober 9, 2024 | finance.yahoo.comWells Fargo Initiates Coverage of Arcus Biosciences (RCUS) with Overweight RecommendationOctober 9, 2024 | msn.comBuy Rating on Arcus Biosciences: Anticipating Casdatifan Success & Strategic Gilead CollaborationOctober 9, 2024 | markets.businessinsider.comArcus Biosciences (NYSE:RCUS) Shares Gap Up - Here's WhyArcus Biosciences (NYSE:RCUS) Shares Gap Up - Here's WhyOctober 8, 2024 | marketbeat.comArcus Biosciences (NYSE:RCUS) Now Covered by Analysts at Wells Fargo & CompanyWells Fargo & Company assumed coverage on shares of Arcus Biosciences in a report on Tuesday. They issued an "overweight" rating and a $29.00 price objective for the company.October 8, 2024 | marketbeat.comBuy Rating on Arcus Biosciences for Innovative ccRCC Treatment and Strategic AstraZeneca CollaborationOctober 7, 2024 | markets.businessinsider.comRenaissance Technologies LLC Sells 158,100 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)Renaissance Technologies LLC reduced its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 65.7% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 82,400 shaOctober 6, 2024 | marketbeat.com Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here RCUS Media Mentions By Week RCUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCUS News Sentiment▼0.230.37▲Average Medical News Sentiment RCUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCUS Articles This Week▼164▲RCUS Articles Average Week Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvalent News Today Blueprint Medicines News Today Krystal Biotech News Today Avidity Biosciences News Today Arcellx News Today BridgeBio Pharma News Today Organon & Co. News Today Biohaven News Today Crinetics Pharmaceuticals News Today Ultragenyx Pharmaceutical News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:RCUS) was last updated on 11/8/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredUrgent: This election is riggedI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
